|
⚕
|
Clinical Takeaway & TL;DR
For the clinician who reads the last page first
|
| Domain | Key Finding | Evidence Level |
| Mechanism | Single peptide with GIP + GLP-1 + glucagon receptor agonism. More potent than native GIP; calibrated lower potency at glucagon to prevent hyperglycemia | Preclinical / Ph1 |
| Weight (Ph2) | 24.2% mean weight loss at 48 weeks (12 mg, no T2D). 100% of 8 mg & 12 mg patients lost ≥5%. Curve still descending at end | Phase 2 RCT — NEJM 2023 |
| Weight (Ph3) | 28.7% mean weight loss at 68 weeks (12 mg, OA population) — avg 71.2 lbs. SBP −14 mmHg. Non-HDL, TG, hsCRP all improved | Phase 3 RCT — TRIUMPH-4, Dec 2025 |
| Liver Fat | 86% relative reduction in liver fat at 48 weeks (12 mg). 93% achieved normal liver fat (<5%). K-18 and Pro-C3 fibrosis markers improved | Phase 2 substudy — Nature Med 2024 |
| T2D Glycemia | HbA1c up to −2.16% at 36 weeks (dose-dependent). 77–82% achieved HbA1c ≤6.5%. Superior to dulaglutide 1.5 mg on all weight and most glycemic endpoints | Phase 2 RCT — Lancet 2023 |
| Eating Behavior | Reductions in hunger, disinhibition, and sweet cravings. Weight loss correlated with disinhibition reduction (r=0.36). 86% noticed changes within 8 weeks | Phase 2 PRO substudy — DOM 2025 |
| Patient Experience | 97% of all retatrutide-treated participants reported appetite/eating changes (across all doses). 88.9% felt self-confident during treatment. 76.7% of participants with weight reduction goals reported achieving them | Qualitative exit interviews — Obesity Pillars 2025 |
| Drug Class Position | Meta-analysis of 55 trials (n=16,269): tri-agonists 24.15 kg vs 11.07 kg (dual) vs 7.03 kg (mono) at 52 weeks. Retatrutide dropout rate below placebo | Meta-analysis — Obesity Pillars 2025 |
| Safety | GI adverse events were most common, concentrated in the dose-escalation period. No hepatotoxicity. ALT/AST declined. Increased lipase and two possible pancreatitis cases (class-consistent). Phase 3 AE discontinuation rates 12.2% (9 mg) and 18.2% (12 mg) vs 4.0% placebo; some due to perceived excessive weight loss | Phase 2 & Phase 3 safety data |
| Regulatory | 7 additional Phase 3 readouts expected 2026. FDA submission Q4 2026–Q1 2027. TRIUMPH-Outcomes (5-year CV/renal) ongoing | Lilly Press Release / ClinicalTrials.gov |
There is a sentence that stopped me when I first read the phase 2 data: 100% of participants in the 8 mg and 12 mg groups lost at least 5% of their body weight.
Not most. Not a majority. Every single one.
In obesity pharmacotherapy, that doesn’t happen—or at least it didn’t, until retatrutide.
Since that initial phase 2 publication in 2023, the evidence base has expanded substantially. We now have a phase 3 readout from TRIUMPH-4. We have a Nature Medicine paper on liver fat. We have patient-reported outcome data and qualitative exit interviews telling us how these effects are experienced subjectively by patients. And we have a rigorous model-based meta-analysis placing retatrutide in the context of the incretin-based therapies across 55 trials and 16,000 patients.
Taken together, the data are difficult to ignore.